VIVUS, Inc. (VVUS) Extends Olive Branch, Follows With Fist

VIVUS, Inc. (NASDAQ:VVUS)Oh, what a difference a day makes.

On Saturday, VIVUS, Inc. (NASDAQ:VVUS) extended an olive branch to its largest shareholder and proxy-fight-adversary First Manhattan, offering to give the hedge fund three board seats whether First Manhattan won seats or not.

Trying to compromise is a good idea, one that I suggested a few weeks ago. Shares have nearly quadrupled since Biogen Idec Inc (NASDAQ:BIIB) ended its proxy fight with investor Carl Icahn by giving one of his nominees a seat on the board. I doubt Icahn’s nominee had that much influence on the success, given that there are 12 directors on the board. But not facing a proxy fight almost certainly helped Biogen Idec Inc (NASDAQ:BIIB) recruit CEO George Scangos, who arguably did have a lot to do with the success.

VIVUS, Inc. (NASDAQ:VVUS)’ niceness was short-lived, though, with the company claiming Sunday that it had reported First Manhattan to the SEC for “false and misleading statements.” The company didn’t actually say what First Manhattan had said except to point out that it was regarding statements about the recommendation of Institutional Shareholder Services, which recommended voting for three of First Manhattan’s nominees.

VIVUS, Inc. (NASDAQ:VVUS) used the issue as a reason (excuse) to delay Monday’s stockholders’ meeting until Thursday. First Manhattan countered suing VIVUS, asking the court to order the inspector of elections to certify the results based on the results that were prepared to be voted at the meeting on July 15.

I doubt the court will agree; for most annual meetings, shareholders have the right to vote at the meeting, so how can we know how shareholders would have ultimately voted if the meeting never occurred?

It seems clear from their actions, though, that both sides believe First Manhattan is leading the proxy fight. No one knows what’s next, but I doubt it’ll involve any compromises.

The real winner
The longer this drags on, the better it is for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Eisai, which sell the obesity drug Belviq that competes directly with VIVUS, Inc. (NASDAQ:VVUS)’ Qsymia. With management and employees distracted by the proxy fight, I doubt marketing of the drug is firing on all cylinders.

If First Manhattan wins, the hedge fund has made it clear it plans to replace CEO Leland Wilson with Anthony Zook, the former president of MedImmune. Even if the switch can take place fairly quickly, it’ll take time to get the new strategy implemented.

Depending on how well VIVUS, Inc. (NASDAQ:VVUS) recovers from the turmoil, the proxy fight could even benefit Orexigen Therapeutics, Inc. (NASDAQ:OREX), which has an obesity drug that could be on the market next year.

If VIVUS, Inc. (NASDAQ:VVUS) somehow pulls a come-from-behind victory, I expect that shares might drop substantially since it seems clear there’s a sizable shareholder base looking for a change.

Investors might also vote in some, but not all, of First Manhattan’s nominees, which would seem to be the worst outcome for VIVUS and therefore the best for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Orexigen Therapeutics, Inc. (NASDAQ:OREX). Internal boardroom fighting would certainly hinder the long-term prospects for Qsymia.

The article VIVUS Extends Olive Branch, Follows With Fist originally appeared on Fool.com and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

Top 6 Cities For The Ultra Rich to Live in Comfort

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!